Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.

Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.

Malignant gliomas are the most common primary brain tumors. Despite intensive clinical investigation and many novel therapeutic approaches, average survival for the patients with malignant gliomas is only about 1 year. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has shown potent...

Full description

Bibliographic Details
Main Authors: Moonsup Jeong, Yong-Sam Kwon, Soon-Hye Park, Chae-Young Kim, Sin-Soo Jeun, Kang-Won Song, Yong Ko, Paul D Robbins, Timothy R Billiar, Byong-Moon Kim, Dai-Wu Seol
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2009-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2641005?pdf=render

Internet

http://europepmc.org/articles/PMC2641005?pdf=render

Similar Items